INNOVATIVE RESEARCH & EDUCATION
The Institute for Biomedical Sciences is training future generations of leading biomedical scientists and professionals through a unique approach to education that highlights the connection among science, business and law and teaches sought-after, technical skills in our advanced labs. Our world-class researchers are tackling some of the most urgent human diseases such as COVID-19, developing new vaccines, diagnostics and therapeutics in research centers focused on microbial pathogenesis, translational immunology and inflammation, immunity and infection.
Breakthroughs in Georgia: Enterprising Biomedicine
In a very short time, Georgia State University has built an impressive research enterprise. It’s the Institute for Biomedical Sciences, and its scientists are unlocking new insights and answers to an array of diseases and ailments. Tens of millions of dollars in research grants flow into the institute each year, and the university is planning even more expansion.
Explore Our Programs
Biomedical Science Research
STOPPING A GLOBAL KILLER
FIGHTING DISEASE THREATS
While humans have encountered some deadly viruses over the centuries such as influenza, Ebola, smallpox, SARS, MERS and HIV, there are inevitably new, life-threatening diseases out there waiting to emerge. Experts have agreed that it wasn’t a question of if – but when – another lethal infectious agent would occur and speculated if the world would be ready to fight it. Sadly, the answer is no.
News Stories & Events
More
Top Stories
Biomedical Sciences Researcher Named One of the World’s Most Highly Cited Scientists for 2021
Dr. Lanying Du, a professor in the Institute for Biomedical Sciences at Georgia State University, has been ranked in the top 1 percent of scientists in the world for having multiple highly cited papers based on field and publication year in the Web of Science citation index.read more ❯
Gilead Sciences Inc. Partners with Center for Translational Antiviral Research to Test Oral Remdesivir Variant
To better reach outpatients early after a COVID-19, infection, Gilead Sciences Inc. has partnered with researchers in Georgia State University’s Center for Translational Antiviral Research to test a modified version of remdesivir that can be taken orally.read more ❯
Preparing for the Next Pandemic
A new research center led by Richard Plemper in the Institute for Biomedical Sciences will develop critical antiviral drugs to meet the challenge of existing and newly evolving threats, such as coronaviruses.read more ❯